CanSino Biologics Inc. (6185) reported that total revenue for the year ended December 31, 2025 reached RMB 1.07 billion, up 26.18% compared to the same period the previous year. Operating profit was RMB 23.91 million, while net profit attributable to shareholders turned positive at RMB 27.87 million. Net loss attributable to shareholders after deducting non-recurring items stood at RMB 92.50 million. The weighted average return on net assets was 0.57%, compared to -7.44% in the previous year.

As of December 31, 2025, total assets amounted to RMB 7.18 billion, down 9.81% from the beginning of the Reporting Period. Equity attributable to shareholders was RMB 4.95 billion, an increase of 0.89%. The company’s share capital reached 247.04 million shares, reflecting a decrease due to the partial cancellation of earlier repurchased A-shares.

The announcement indicated that consistent revenue growth was supported by the performance of Menhycia® in the Chinese market and effective cost-control measures. Non-recurring income also contributed to the improved profit. The above data remains preliminary, unaudited, and subject to final confirmation in the company’s 2025 annual report.